Wednesday, July 8, 2026

pharma · Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors · Atopic Dermatitis · HOTH

Hoth Therapeutics

HotHouse Therapeutics is a pharma organization headquartered in Norwich, GB. It trades on NYSE under ticker HOTH. Primary therapeutic focus areas include Skin Toxicities Associated with Epidermal Growth Factor Receptor I

Norwich, GB HQ
12 Employees
Public company Type
HOTH · NYSE Ticker
Company details
Status
Public
HQ
Norwich, GB
Employees
12
Programs
3
Drugs
4
Patents
1
Clinical program

BioLexa- Cohort 1

Phase 1 · small molecule · Atopic Dermatitis

BioLexa- Cohort 1 for Atopic Dermatitis is a Phase 1 program (small_molecule) at Hoth Therapeutics with 1 ClinicalTrials.gov record(s).

← All Hoth Therapeutics projects Phase 1 small molecule completed

Internal code AD-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoth Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Atopic Dermatitis
Status
completed
Trials
1

Clinical trials